The FDA has relaxed a clinical hold on clinical trials of Novartis' intrathecal formulation of spinal muscular atrophy (SMA) gene therapy Zolgensma, allowing a new phase 3 trial to get underway.
King Faisal Specialist Hospital & Research Centre continues to strengthen its position as a leading referral center for pediatric hematology and oncology through a comprehensive care model built on ...
Khaleej Times on MSN
Fakeeh University Hospital sets new benchmarks in advanced gene therapy
Fakeeh University Hospital is emerging as a global destination for advanced gene therapy, delivering highly specialised ...
Il Medcare Women & Children Hospital ha somministrato con successo una terapia genica intratecale pionieristica per l'atrofia ...
This milestone positions Medcare among the first private healthcare providers worldwide to offer this innovative treatment to an older international patient, overcoming previous age and weight limitat ...
The newly licensed intrathecal gene therapy expands life-changing treatment options for children and adults affected by ...
En el Hospital Medcare Women & Children se ha administrado con éxito una terapia génica intratecal pionera para la atrofia ...
Medcare Women & Children Hospital has successfully administered a pioneering intrathecal gene therapy for Spinal Muscular ...
The global pain management therapy market size was US$ 3.5 billion in 2021. The global pain management therapy market is forecast to grow to US$ 7.6 billion by 2030 by growing at a compound annual ...
Manitoba appears to be expanding the spinal care capacity it set out to when it disbanded a stopgap measure by the Tories ...
Licensed intrathecal gene therapy enhances treatment for Spinal Muscular Atrophy patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback